Pull incentives for antibiotics: Duke-Margolis PAVE policy paper and PBS Newshour segments

Dear All: 

We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this!

Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to the voices calling for new economic models for antibiotics.

First, the Duke-Margolis Center for Health Policy has released both a White Paper and a viewpoint paper in JAMA describing the elements of a Priority Antimicrobial Value and Entry (PAVE) Award proposal that could be a path for the diverse and complex US market to create such a model. PAVE combines a market entry reward with population-based payments from public and private payers that phase in over time.

Second, PBS Newshour is doing a Stopping Superbugs series in which their science and economic correspondents have collaborated to tell this story. The first three episodes are out:

2 Aug 2017: We are running out of effective antibiotics
3 Aug 2017: The financial barrier
4 Aug 2017: Is there an economic cure for the problem?

We have yet to turn any of this into concrete action, but steadily expanding the conversational echo chamber is a necessary prelude to such action. I’m looking forward to the rest of the PBS broadcasts, and then next up, I think, will be the output from DRIVE-AB in early September. Stay tuned!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

JPIAMR Diagnostics Call / James Bond’s occupational exposures

Dear All, A short one today! Please peruse both the funding opportunities and upcoming meetings just below my signature. Of special note: Building on the call in the recent biodefense-focused BAA from NIAID for diagnostic applications, JPIAMR is also looking for diagnostic applications (7 Mar deadline). Very interesting 2 Mar 2023 Duke-Margolis webinar entitled “Data Capture

NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more

Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check

LPAD/Limited Use insights; NI margins for TB and candidiasis

Dear All,  I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here.  Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion

Notable webinars: Pediatric drug development; Drug delivery systems

Dear All, The high-value webinars below have just crossed my radar.  First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the

Scroll to Top